Ketamine can be addictive, though the risk varies enormously depending on how much a person uses, how often, and in what setting. In clinical contexts, where doses are low and tightly controlled, dependence is rare but has been documented in a handful of case reports. In recreational settings, where cumulative exposure can be more than 90 times higher, dependence develops much more readily, complete with cravings, tolerance, and a withdrawal syndrome that includes low mood, anxiety, and sleep problems. The gap between those two realities is where most of the confusion around ketamine lives, and the neuroscience beneath it turns out to be surprisingly tangled.
Why the Brain Finds Ketamine Rewarding
Ketamine’s best-known action is blocking a receptor called NMDA, which is involved in how brain cells communicate through the chemical messenger glutamate. When ketamine blocks that receptor, it triggers a cascade that actually increases glutamate release in the prefrontal cortex, a region critical for decision-making and mood regulation.1Europe PMC / Nature Publishing Group. The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects This surge of glutamate is thought to be part of why ketamine works so fast against depression, but it also contributes to the dissociative, floaty feeling that recreational users seek.
The NMDA story alone would not fully explain addiction, though. Ketamine also increases dopamine levels in the nucleus accumbens, the brain’s core reward hub. A meta-analysis of rodent studies found a large effect: animals given ketamine showed significantly elevated dopamine compared to controls.2PubMed Central. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders That dopamine hit is a classic ingredient in the recipe for compulsive drug-seeking. One research group, though, reported that ketamine actually reduced dopamine release in the nucleus accumbens and blocked certain forms of synaptic strengthening there, while enhancing it in a connected region called the ventral tegmental area.3Featured Abstracts Neuroscience. The Use of Ketamine to Alter Mesolimbic Reward Pathway Neuronal Components that Underlie Addiction Pathophysiology The disagreement hints that dose, timing, and the specific brain region being measured all matter, and that the dopamine picture is not as simple as “more dopamine equals more addiction.”
More recently, researchers have zeroed in on a third system: the brain’s own opioid receptors. A small but striking clinical trial found that when people received the opioid blocker naltrexone before a ketamine infusion, the antidepressant effect was dramatically blunted.4PubMed Central. Opioid Receptor Antagonism Attenuates Antidepressant Effects of Ketamine Animal work has since traced some of ketamine’s acute behavioral effects to mu opioid receptors on neurons in a brain region called the central amygdala, which is involved in emotional processing and fear.5PubMed Central. Ketamine Evokes Acute Behavioral Effects Via μ Opioid Receptor-Expressing Neurons of the Central Amygdala The implication is uncomfortable but important: the same opioid-receptor engagement that may help ketamine lift depression could also contribute to its rewarding and potentially habit-forming properties.6PubMed Central. Bifunctional Modulation of NMDA and Opioid Receptors in Ketamine Reinforcement and Misuse: Implications for Substance Use Disorder Treatment In other words, the therapeutic effects and the abuse potential are not neatly separable; they appear to be wired through overlapping circuits.
What Ketamine Dependence Actually Looks Like
People who develop ketamine use disorder describe a recognizable pattern of withdrawal symptoms when they stop. In a study that surveyed people seeking help for ketamine dependence, about seven in ten reported cravings during abstinence, roughly six in ten reported low mood, and a similar proportion reported anxiety. Irritability, sleep disturbances, fatigue, and abdominal pain were also common.7PubMed Central. The landscape of ketamine use disorder: Patient experiences and perspectives on current treatment options This is not the life-threatening physical withdrawal seen with alcohol or benzodiazepines, but it is real and sustained enough to drive relapse.
Craving intensity appears to track with depression severity. In a study of people undergoing withdrawal treatment, those with stronger cravings also had worse depressive symptoms, and people who stayed in treatment longer than two weeks tended to experience both more cravings and deeper depression than those who left earlier.8PubMed. Association of Craving and Depressive Symptoms in Ketamine-Dependent Patients Undergoing Withdrawal Treatment That intertwining of mood and craving creates a feedback loop: people who initially sought ketamine to escape low mood find that stopping it makes the mood worse, which in turn fuels the urge to use again.
Tolerance builds quickly. In primate studies, repeated sub-anesthetic doses produced tolerance in all animals tested, though the speed and degree varied widely between individuals.9PubMed. Rapid development of tolerance to sub-anaesthetic dose of ketamine: an oculomotor study in macaque monkeys In rats, two weeks of daily ketamine injections produced dose-dependent tolerance to the anesthetic effect, and interestingly, chronic morphine also produced cross-tolerance to ketamine, while cocaine did not.10PubMed Central. Ketamine Tolerance in Sprague-Dawley Rats after Chronic Administration of Ketamine, Morphine, or Cocaine That cross-tolerance with opioids reinforces the idea that ketamine’s opioid-receptor activity is not just a laboratory curiosity; it has real pharmacological consequences.
The Massive Dose Gap Between Clinic and Club
One of the most important numbers in the ketamine-addiction conversation is the cumulative dose difference between supervised medical use and recreational use. A systematic review comparing the two found that heavy recreational users accumulate more than 90 times the total ketamine exposure of patients receiving clinical treatment for conditions like depression.11PubMed. Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study That difference helps explain why serious side effects and dependence are overwhelmingly reported in recreational users, and why adverse events in the clinical setting tend to be mild and reversible.
That said, clinical use is not entirely risk-free. A systematic review of the literature on ketamine for depression found that among all studied patients, four showed clear signs of either tolerance to the antidepressant effect or drug dependence, while the large majority did not.12PubMed. Is there a risk of addiction to ketamine during the treatment of depression? A systematic review of available literature A handful of individual case reports have also documented full-blown addiction developing after clinical ketamine treatment for depression.13PubMed Central. On the safety of repeated ketamine infusions for the treatment of depression: Effects of sex and developmental periods The numbers are small, but they are not zero, and they underscore the need for structured monitoring even in controlled settings. The risk is highest for people with a personal history of substance use problems, which most clinical protocols already screen for.
S-Ketamine Versus R-Ketamine
Ketamine is actually a mixture of two mirror-image molecules, called enantiomers. The version approved by the FDA as a nasal spray for treatment-resistant depression is esketamine, the S-enantiomer. Its mirror twin, arketamine (the R-enantiomer), is not yet approved but has attracted interest precisely because it may carry lower abuse potential.
In laboratory studies, arketamine has about one-quarter the affinity for the NMDA receptor compared to esketamine. Despite that, animal models suggest arketamine produces stronger and longer-lasting antidepressant effects, with less dopamine release in the prefrontal cortex and fewer psychomotor side effects.14PubMed Central. Ketamine or Esketamine in Special Populations of Patients With Treatment-Resistant Depression Researchers have proposed that esketamine is the primary driver of ketamine’s reinforcing properties and misuse potential, largely because of its stronger engagement with both NMDA and mu opioid receptors.6PubMed Central. Bifunctional Modulation of NMDA and Opioid Receptors in Ketamine Reinforcement and Misuse: Implications for Substance Use Disorder Treatment If arketamine continues to show this profile in human trials, it could eventually offer a way to get ketamine’s benefits with a lower risk of dependence, though this remains unproven in clinical practice.
What Animal Studies Reveal About Self-Administration
One way researchers gauge a drug’s addictive potential is by letting animals press a lever to receive doses. Rats will self-administer ketamine, but only at higher doses; they show clear reinforcement at the top of the tested range and largely ignore the drug at low doses.15PubMed Central. Exploring ketamine’s reinforcement, cue-induced reinstatement, and nucleus accumbens cFos activation in male and female long evans rats In human terms, this suggests there may be a threshold below which ketamine is not particularly habit-forming, but above which it becomes genuinely reinforcing.
Sex differences show up consistently. Female rats self-administered ketamine at a higher rate than males at the highest dose tested.15PubMed Central. Exploring ketamine’s reinforcement, cue-induced reinstatement, and nucleus accumbens cFos activation in male and female long evans rats Hormonal status also appears to matter: in one study, female rats tested during the proestrus phase of their cycle behaved similarly to males in drug-seeking, while those in diestrus showed significantly less interest in pursuing the drug.16PubMed Central. Reinforcing properties of an intermittent, low dose of ketamine in rats: effects of sex and cycle Drug-paired environmental cues were a powerful trigger for relapse-like behavior in both sexes, but ketamine alone, without those cues present, was not enough to restart drug-seeking.16PubMed Central. Reinforcing properties of an intermittent, low dose of ketamine in rats: effects of sex and cycle That detail is relevant for humans too: the environmental setting in which someone uses ketamine, whether it is a party, a particular room, or a group of friends, may play a big role in driving habitual use.
Physical Damage From Chronic Use
The organ that takes the hardest hit from chronic ketamine use is the bladder. A condition known as ketamine-induced cystitis has become one of the most distinctive and distressing consequences of heavy recreational use. Ketamine and its breakdown products are excreted in urine, and prolonged contact with the bladder lining causes severe inflammation, damages the protective barrier of the bladder wall, and can lead to fibrosis.17PubMed Central. Ketamine-Induced Cystitis: A Comprehensive Review of the Urologic Effects of This Psychoactive Drug Symptoms include intense bladder pain when the bladder is full, frequent and painful urination, and recurrent urinary tract infections.18PubMed Central. Pathophysiology, clinical presentation, and management of ketamine-induced cystitis
Animal research has shown that the mechanism involves oxidative stress: ketamine treatment increases harmful reactive molecules in bladder tissue while simultaneously reducing the body’s own antioxidant enzymes, leading to cell death in the bladder wall and disruption of the proteins that hold the lining together.19PubMed. Ketamine-induced ulcerative cystitis and bladder apoptosis involve oxidative stress mediated by mitochondria and the endoplasmic reticulum In advanced cases, if use continues, the damage can extend upward to the ureters and kidneys, potentially causing strictures, reflux of urine, and even kidney failure.18PubMed Central. Pathophysiology, clinical presentation, and management of ketamine-induced cystitis The good news is that early-stage cystitis can improve substantially if a person stops using ketamine. Once fibrosis sets in, the damage becomes much harder to reverse.
How Long-Term Use Reshapes the Brain
A systematic review of neuroimaging studies in chronic recreational ketamine users found consistent structural and functional changes. Users had lower gray matter volume and reduced cortical thickness, particularly in the frontal, parietal, and occipital regions. White matter integrity was also diminished, especially in frontal and temporoparietal areas.20PubMed Central. Brain Changes Associated With Long-Term Ketamine Abuse, A Systematic Review These regions are involved in memory, attention, and executive function, which aligns with the cognitive complaints that long-term users commonly report: difficulty remembering things, trouble concentrating, and slower thinking.
White matter changes may also help explain the dissociative experiences that persist even between uses. A separate imaging study found disrupted white matter integrity across a right-hemisphere network in chronic ketamine users, and the degree of disruption between certain brain structures and the prefrontal cortex predicted how strong their dissociative experiences were.21Neuropsychopharmacology. Abnormalities in White Matter Microstructure Associated with Chronic Ketamine Use In short, heavy use does not just produce temporary disconnection from reality during a session; it remodels the wiring in ways that can make dissociation a semi-permanent feature of a person’s mental life.
Rising Nonmedical Use in the U.S.
For most of the 2000s and 2010s, nonmedical ketamine use in the United States remained relatively rare, with past-year use hovering under two-tenths of a percent of the population aged 12 and older. That changed after 2021. Between 2021 and 2023, estimated past-year use among people aged 12 and older nearly doubled, rising from about 0.19% to about 0.34%.22The Lancet Regional Health – Americas. Trends in illicit ketamine availability, nonmedical use, poisonings, and mortality in the USA: an observational study of national datasets Among adults aged 18 and older, the jump was from 0.20% to 0.37% over the same period. The increase coincides with greater awareness of ketamine’s use in mental health treatment and a boom in at-home ketamine telehealth services, though the data do not establish which factor, if any, is driving the trend.
The typical recreational user is young. A large global survey found a mean age of about 27, with the majority identifying as male.23PubMed Central. Ketamine use in a large global sample: Characteristics, patterns of use and emergency medical treatment Among adolescents aged 12 to 17 in the U.S., however, there was actually a decline in use between 2010 and 2014, and rates have not shown the same upswing seen in adults.22The Lancet Regional Health – Americas. Trends in illicit ketamine availability, nonmedical use, poisonings, and mortality in the USA: an observational study of national datasets
Polysubstance Use and Compounded Risk
Ketamine is rarely used in isolation recreationally. Alcohol is one of the most commonly co-used substances, and the combination is pharmacologically risky because ketamine and alcohol share several molecular targets, particularly around NMDA receptors and inhibitory signaling in the brain.24PubMed Central. Ketamine plus Alcohol: What We Know and What We Can Expect about This The concern is that combining the two could amplify both the acute effects, such as sedation and impaired coordination, and the longer-term toxic consequences, including during withdrawal.
Human lab studies in healthy volunteers have also shown that ketamine impairs response inhibition, the ability to stop yourself from doing something impulsive, and this impairment was dose-dependent.25SpringerLink / Psychopharmacology. Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose-response study That loss of impulse control under the influence helps explain why someone who starts with a planned single dose at a party might escalate within the same session, and why combining ketamine with other disinhibiting substances is a recipe for poor decisions.
Overdose Risk and Acute Harm
Pure ketamine overdose is rarely fatal. A review of ketamine-related deaths found that most were not caused by the drug’s direct toxicity but by the dangerous situations or activities people engaged in while impaired, like drowning, falls, or car crashes.26International Journal of Drug Policy. The health and psycho-social consequences of ketamine use Ketamine maintains breathing and airway reflexes at typical doses better than most other sedatives, which is part of why it became popular in emergency medicine in the first place.
That relative pharmacological safety, though, can breed complacency. Acute adverse effects from recreational use include impaired consciousness, dizziness, irrational behavior, hallucinations, abdominal pain, and vomiting. When someone presents to an emergency department with acute ketamine toxicity, treatment is mostly supportive, with benzodiazepines recommended as first-line therapy for agitation and elevated blood pressure.27PubMed. The clinical toxicology of ketamine The real danger is not usually the drug itself but the state of impaired judgment and dissociation it produces, particularly in uncontrolled environments.
Where Treatment Stands
There is no approved medication specifically for ketamine use disorder. Treatment currently relies on behavioral approaches, and a recent systematic review proposed that the timing of psychotherapy relative to neuroplastic recovery phases, the windows in which the brain is actively remodeling after stopping ketamine, could matter for outcomes.28PubMed. Breaking the cycle: a systematic review of neurobiological mechanisms and psychotherapeutic innovations in ketamine addiction This is still a framework more than a proven protocol, though, and reflects how early the field is. Animal research has explored whether blocking certain molecular pathways, like those involving the enzyme GSK-3β, can reduce relapse to ketamine-seeking. In rats, a selective GSK-3β inhibitor suppressed both cue-triggered and drug-triggered reinstatement of ketamine seeking.29Drug and Alcohol Dependence. The effects of GSK-3β blockade on ketamine self-administration and relapse to drug-seeking behavior in rats These are early leads, not treatments you can ask a doctor for today.
For now, the practical picture for someone concerned about ketamine dependence involves standard addiction-medicine approaches: tapering use when possible, treating the anxiety and depression that often co-travel with ketamine craving, and addressing the environmental triggers that laboratory studies consistently show are powerful drivers of relapse. The lack of a targeted pharmacotherapy means that preventing dependence in the first place, by keeping doses low, sessions infrequent, and monitoring structured, remains the most reliable strategy.